PTAB Rejects Amgen's Bid For Humira Patent Reviews

The Patent Trial and Appeal Board on Thursday denied two requests by Amgen for reviews of two AbbVie patents covering the megablockbuster Humira, just months after Amgen had asked the U.S. Food and...

Already a subscriber? Click here to view full article